Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution

Area of Science:

• Nanomedicine
• Molecular Imaging
• Cancer Biology

Background:

• Understanding nanoparticle drug distribution in tumors is crucial for nanomedicine design and clinical use.
• Current methods lack comprehensive views of nanomedicine spatio-temporal behavior within complex tumor microenvironments.

Purpose of the Study:

• To develop and apply a novel multi-modal imaging approach combining Mass Spectrometry Imaging (MSI) and Imaging Mass Cytometry (IMC).
• To assess the biodistribution of nanoparticle-delivered drugs and their metabolites in pre-clinical tumor models.
• To correlate nanomedicine distribution with tumor microenvironment markers.

Main Methods:

• Integration of MSI and IMC for co-registered molecular and spatial data acquisition.
• Assessment of AZD2811 nanomedicine (PLA-PEG nanoparticles) in three patient-derived xenograft (PDX) tumor models.
• Direct visualization and differentiation of nanoparticle-formulated drug versus free drug distribution.

Main Results:

• MSI differentiated nanoparticle drug distribution from co-administered free drug, revealing heterogeneous nanomedicine distribution.
• Integrated MSI and IMC data identified associations between nanomedicine distribution and tumor microenvironment features like macrophages and stroma.
• Quantitative analysis enabled delineation of drug abundance within specific cell types and stromal regions.

Conclusions:

• The developed multi-modal imaging solution provides deeper insights into drug and nanocarrier distribution within complex tissues.
• This approach facilitates a data-driven approach to optimize nanomedicine design and enhance clinical translation.
• Improved understanding of nanomedicine behavior in vivo is essential for advancing cancer therapy.